

## HSV-2 (G Strain) Purified Viral Lysate

Catalog Number: 10-146-000

Lot Number: 6F0021-VL

Product Description: Herpes Simplex Virus type 2 (G strain) purified virus lysed with Triton X-100.

Cell Line for Propagation: Vero Cells

Unit Size: 1.0 mg

Fill Volume: 1.0 mL

Suspending Buffer: 10 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.5 with 0.5% Triton X-100

### QUALITY CONTROL DATA

Sterility Tests: Bacteria, yeasts, and fungi were not detected (USP-NF). Mycoplasma was not detected by MycoAlert™ Mycoplasma Detection Kit (Lonza, LT07).

Protein Concentration: 1.0 mg/mL determined by Pierce BCA protein assay using BSA standard. Alternative methods for determining protein concentration may give different values.


Virus Particle Count (VPC) by TEM:  $5.7 \times 10^9$  vp/mL (active virus, prior to lysis)

Validation of Inactivation: This lot of viral lysate has been specifically tested for residual infectivity and no infectious virus was detected. The lysate was titrated in Vero cells over a 7-day period with endpoint determination by cytopathic effect (CPE). Purified virus of the same viral stock and mock-infected Vero cells were included as positive and negative controls, respectively, for the assay. The positive control yielded an infectivity titer of  $10^{8.17}$  TCID<sub>50</sub>/mL.

ELISA Testing: 22,864 units\*/mL using HSV-2 gG MAb.  
0 units\*/mL using HSV-1 gG MAb.

\*A unit is defined as the reciprocal dilution that gives an absorbance of 0.500 in our test system.

ELISA Reactivity of HSV-2G Viral Lysate Lot.6F0021-VL with HSV-2 gG and HSV-1 gG MAbs



Western Blot Testing: Reactive in Western Blot using HSV-2 gG MAb and non-reactive using HSV-1 gG MAb.

### PRODUCT DETAILS

Shipping and Storage: This product is shipped frozen on dry ice. **Store at -70°C upon receipt.** Avoid multiple freeze-thaw cycles as product degradation may result.

Recommendations: Upon thawing, if any precipitate of proteinaceous material is observed, pulse vortex until the precipitate is completely resuspended. Use immediately following resuspension.

Safe Handling Recommendation: This inactivated biological preparation should be handled in accordance with biosafety guidelines defined in the BMBL, NIH-CDC HHS Publication No. (CDC) 21-1112.

References: 1. Delagrave, S., et al. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model. PLoS ONE 2011.

2. Mundle, S. T., et al. High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo. PLoS ONE 2013.

This product is for research use only.  
Not for use in diagnostic procedures.

*[Signature]*  
Quality Control

07-13-2015  
Date

Quick. Easy. **Technical support.**  
[www.abionline.com/contact-us/](http://www.abionline.com/contact-us/)



**CERTIFICATE OF ANALYSIS**